Ming De Biotech: Stock May Be Subject to Delisting Risk Warning

CryptocurrencySniper · 2026-03-22T08:02:48+00:00

Mingde Biology expects to face a total profit loss of 50 million to 75 million yuan in 2025, a net loss of 15 million to 25 million yuan, a non-GAAP net loss of 100 million to 140 million yuan, and operating revenue between 237 million to 297 million yuan, and may face a delisting risk warning.

CryptocurrencySniper

2026-03-22 08:02:48

Abstract generation in progress

Mingde Biology (002932.SZ) announced that the company expects a total profit loss of 50 million to 75 million yuan in 2025, a net profit loss of 15 million to 25 million yuan, a non-recurring net profit loss of 100 million to 140 million yuan, and an operating revenue after deductions of 237 million to 297 million yuan. Due to negative net profit and revenue after deductions below 300 million yuan, the company’s stock may be subject to delisting risk warning (*ST) after the 2025 annual report is disclosed. The annual audit is still ongoing, and final data will be based on the audited annual report.

(Source: Cailian Press)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes